and Development Officer
Shane Bowen, Ph.D. is the Chief Research and Development Officer at SomaLogic and is responsible for all aspects of the company's technology, scientific and development functions. He oversees product innovation across the Core Science, Bioinformatics & Data, Engineering, Software and Platform Innovation groups.
Prior to joining SomaLogic, Dr. Bowen held several roles at Illumina where he was foundational to the development of the chemical patterning technology that delivered commercialization the $1,000 genome in 2014 as the HiSeq X platform and enabled the trajectory to deliver the $100 genome, commercialized in 2017 as the NovaSeq platform. In 2020, Dr. Bowen co-founded Palamedrix, serving as President and Chief Executive Officer, leading the charge to build a DNA nanotechnology-based platform for single molecule protein identification and quantification. In 2022, Palamedrix was acquired by SomaLogic and Dr. Bowen was hired by the company as Vice President of Technology Development.
Shane earned his B.S. in Physics and Mathematics from the University of San Francisco in 1998. In 2000 he completed his M.S. in Applied Physics and in 2005 his Ph.D. in Physical Chemistry, both from the University of California, San Diego.